Quick-release bromocriptine is a new formulation of bromocriptine mesylate that the FDA approved in May 2009 for the treatment of type 2 diabetes. Bromocriptine is an ergot alkaloid dopamine D2 ...

The authors compare the treatment of hyperprolactinemic men and women using dopamine-receptor agonists bromocriptine and the newer drug cabergoline. They describe similarities and differences in ...

Bromocriptine, a drug previously used to treat adults with type 2 diabetes and Parkinson’s disease, improved BP and central and peripheral aortic stiffness over 4 weeks in adolescents with type ...

Bromocriptine is unique in that it does not have a specific receptor that mediates its action on glucose and lipid metabolism. Rather, its effects are mediated via resetting of dopaminergic and ...

(HealthDay)—Serious adverse drug reactions (ADRs) can occur after bromocriptine use in lactation inhibition, most of which could be avoided, according to a study published online March 11 in ...

Bromocriptine quick release (BCQR) improves blood pressure and central and peripheral aortic stiffness and pressure hemodynamics in adolescents with type 1 diabetes (T1D), a placebo-controlled ...

Drug repurposing shows promise in the treatment of retinal degenerations, according to a new study. A combination treatment incorporating three existing drugs -- tamsulosin, metoprolol and ...

Drug repurposing shows promise in the treatment of retinal degenerations, according to a new study by an international team of researchers, published in Nature Communications. A combination ...

Due to the study’s small sample, further research is needed to understand the role of bromocriptine in reducing blood pressure and artery stiffness in youth with type 1 diabetes (T1D).

29 adolescents referred for excessive height prediction (HP) (9 boys with HP > 195 cm, 20 girls with HP > 180 cm) were treated for 9 to 15 months with bromocriptine (5 to 7.5 mg/day). Minor and ...

Bromocriptine Improves Central Aortic Stiffness in Adolescents With Type 1 Diabetes: Arterial Health Results From the BCQR-T1D Study. Hypertension, 2022; DOI: 10.1161/HYPERTENSIONAHA.122.19547; ...

Drug repurposing shows promise in the treatment of retinal degenerations, according to a new study by an international team of researchers, published in Nature Communications. A combination ...